SUPPLEMENT

Q2 2023 — Earnings supplement

Q2 2023PDF · 3 pages151 KB
BIOPROCESSING
Color on what we are seeing in Bioprocessing today:
1) Destocking continued as we moved through Q2
• 	Large Pharma working through inventory they built during the pandemic
• 	Emerging biotech still down as they conserve capital
2) In China, ongoing market correction accelerated as Q2 progressed
3) Given these dynamics, we’ve begun to more actively work with customers to manage down
inventory levels
Q2 2023 RESULTS
Q2 Core revenue growth -7.0%, in-line with expectations despite lower bioprocessing revenue
Q2 base business core revenue growth +2.0%, base business core growth by segment:
• 	Biotechnology -HSD
o 	Bioprocessing -HSD
• 	LS +HSD
o 	Life sciences instruments +MSD
• 	Dx +HSD
o 	Non-respiratory testing at Cepheid +>30%
o 	LBS +HSD, Bec Dx +MSD
• 	EAS +1.5%
o 	WQ +MSD
o 	PID -MSD
COVID revenues
• 	Cepheid’s respiratory testing revenue of ~$300M in Q2 was above our expectation of ~$175M
driven primarily by positive mix of 4-in-1 test vs. COVID-only tests and slightly higher than
expected volume
• 	COVID Vx/Tx revenue in Q2 was ~$30M
Q2 Adjusted OP margins of 26.5% slightly above our expectations
Q2 Adjusted EPS of $2.05
YTD 2023 Free Cash Flow (FCF) was ~$3.3B with FCF to net income conversion of >125%

-- 1 of 3 --

Q3 / FY 2023 GUIDANCE
Anticipated Q3 and FY 2023 Core Growth
• 	FY 2023 revenue assumptions for our businesses remain largely consistent with our prior
guidance with the exception of bioprocessing base business growth
• 	In bioprocessing, we anticipate FY 2023 base business core revenue growth will be down ~10%
for the full year
Anticipated Q3 and FY 2023 Adjusted Operating Profit Margin
FY 2023
• 	We anticipate adjusted operating profit margin of ~29%
• 	Change vs prior expectation of ~30% is due primarily to lower expected base business revenues
in bioprocessing
Q3 2023
• 	We anticipate adjusted operating profit margin of ~26%
• 	This includes continued impact of capacity reduction costs which began in Q2
2023 Model Items
COVID
• 	Anticipate Cepheid testing revenue of $100M in Q3 and $1.2B for FY 2023
• 	Anticipate Vx/Tx revenue of $150M for FY 2023
Corporate expense (excluding EAS Separation costs): ~$80M in Q3 and ~$310M for FY 2023
Adjusted non-operating income: ~$2M per quarter for remainder of 2023
Assumed Interest expense, net: ~$10M in Q3 and ~$40M for FY 2023
Tax rate: ~19.5% for Q3 and FY 2023
Average adjusted diluted shares
• 	~747M for Q3
• 	~747M for FY 2023

-- 2 of 3 --

FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will
or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors
that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking
statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future,
adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on
our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to
national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth
rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new
markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations
(including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical
trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully
identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to
integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other
risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and
future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the
impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency
exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and
other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with
respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using
government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and
availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our
channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and
services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating
to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and
skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of the military conflict between Russia and
Ukraine), disruptions relating to man-made and natural disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive
forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is
available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2023. These
forward-looking statements speak only as of the date of this document and except to the extent required by applicable law, the Company does not assume
any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
With respect to the non-GAAP financial measures referenced above, definitions and the accompanying information required by SEC Regulation G can be
found in the document accompanying this note or in the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial
Reports” and subheading “Quarterly Earnings.”

-- 3 of 3 --